Royalty Pharma plc and Teva Pharmaceuticals have signed a funding agreement worth up to $500 million to expedite the clinical development of Teva’s anti-IL-15 antibody, TEV-408. IL-15 plays a vital role in various immune-mediated diseases. Early Phase 1b data from Teva’s vitiligo study indicate IL-15 could be a promising treatment for autoimmune conditions. Teva plans to share trial results in 2026. Royalty Pharma will provide up to $500 million to support the development costs for TEV-408, with $75 million allocated for a Phase 2b study starting in 2026. If successful, Royalty Pharma has the option to contribute an additional $425 million for Phase 3 development. Teva will pay Royalty Pharma milestone payments and royalties on worldwide sales if TEV-408 is approved and launched. Visit rttnews.com for more health news.

Read more at Nasdaq: Royalty Pharma And Teva Announce $500 Mln Funding Agreement For TEV-408 Development